The
NICE Equation

NICE (the National Institute for Health and Care Excellence) was founded in 1999 to solve a specific, politically toxic problem: the postcode lottery. Before NICE, each local health authority made its own decisions about which drugs to fund. If you lived in one county, you might get a breakthrough cancer drug; if you lived ten miles down the road, you might be denied it. The system was wildly inconsistent and deeply unfair.

NICE was designed to be the single, evidence-based arbiter. Its core function is the technology appraisal — evaluating whether a new drug or treatment is cost-effective enough for the NHS to pay for. This is rationing, but it is rationing abstracted into a highly sophisticated mathematical framework. Most countries do not have anything like it; they either rely on private insurance markets or less rigorous state negotiations.

When NICE appraised Wegovy (semaglutide) and Mounjaro (tirzepatide), they didn't just look at weight loss. They looked at the long-term economic model. The most controversial assumption in that model was what happens when patients stop taking the drug.

Clinical trials show that patients regain roughly two-thirds of their lost weight within a year of stopping a GLP-1. This reduces the lifetime QALY gain significantly. The manufacturer's submission argued for sustained benefits; NICE's independent assessment was far more sceptical.

To make the maths work and get below the £30,000/QALY threshold, the manufacturers (Novo Nordisk and Eli Lilly) had to offer the NHS a confidential discount. The list price you see in the British National Formulary is a fiction. The true price is a closely guarded state secret, ensuring the NHS gets a deal without collapsing the global pricing structure for these blockbuster drugs.

Does prevention actually save money? This is the most contested question in health economics. The NHS spends an estimated £6.5 billion per year treating obesity-related conditions: type 2 diabetes, cardiovascular interventions, joint replacements, and certain cancers.

If GLP-1s reduce obesity at a population scale, the savings could be enormous. But there is a structural flaw in how the state accounts for this: the costs are immediate, but the savings materialise 10 to 20 years later.

A drug that looks terrible on this year's budget looks brilliant on a 20-year model. This temporal mismatch makes rational long-term healthcare investment almost impossible within the current NHS funding structure. We accept upfront costs for childhood vaccinations because the political consensus is absolute. For obesity, the evidence base is newer, and the political will is significantly weaker.

Ultimately, the NICE equation forces a society to answer an uncomfortable ethical question. One view holds that obesity is a chronic medical condition driven by genetics, environment, and hormonal signalling; treating it with medication is no different from treating hypertension.

The opposing view argues that prescribing lifelong, expensive medication for a condition that can often be addressed through diet and exercise medicalises a lifestyle problem and creates pharmaceutical dependency, draining resources from other acute NHS services.

The middle ground, where the NHS currently sits, is an awkward compromise: GLP-1s work, but the state cannot afford to be the primary funder of a treatment that private patients are already buying in enormous quantities.

The spreadsheet has spoken. Until the patent expires, your access to the most effective weight loss drug in history depends entirely on whether your future illnesses are expensive enough to prevent today.